Depressive DisordersAnxiety DisordersSubstance Use Disorders (SUD)Palliative & End-of-Life DistressSchizophreniaCreativityImmunology & InflammationPublic Health, Prevention & Behaviour Change

Self-Entropic Broadening Theory: Toward a New Understanding of Self and Behavior Change Informed by Psychedelics and Psychosis

This review (2022) provides a theory of how changes due to (classical) psychedelics and psychosis have such different (positive vs negative) outcomes. This is done through the lens of self-entropic broadening theory (broader attentional scope, hyperassociative thinking), where psychedelics lead to low self-focus (awe, ego dissolution, mystical experiences), whilst psychosis leads to high self-focus (hyperreflexivity, self-referential processing).

Authors

  • Peter Hendricks

Published

Pharmacological Reviews
meta Study

Abstract

The extremes of human experiences, such as those occasioned by classic psychedelics and psychosis, provide a rich contrast for understanding how components of these experiences impact well-being. In recent years, research has suggested that classic psychedelics display the potential to promote positive enduring psychologic and behavioral changes in clinical and nonclinical populations. Paradoxically, classic psychedelics have been described as psychotomimetics. This review offers a putative solution to this paradox by providing a theory of how classic psychedelics often facilitate persistent increases in well-being, whereas psychosis leads down a “darker” path. This will be done by providing an overview of the overlap between the states (i.e., entropic processing) and their core differences (i.e., self-focus). In brief, entropic processing can be defined as an enhanced overall attentional scope and decreased predictability in processing stimuli facilitating a hyperassociative style of thinking. However, the outcomes of entropic states vary depending on level of self-focus, or the degree to which the associations and information being processed are evaluated in a self-referential manner. We also describe potential points of overlap with less extreme experiences, such as creative thinking and positive emotion-induction. Self-entropic broadening theory offers a heuristically valuable perspective on classic psychedelics and their lasting effects and relation to other states by creating a novel synthesis of contemporary theories in psychology.

Unlocked with Blossom Pro

Research Summary of 'Self-Entropic Broadening Theory: Toward a New Understanding of Self and Behavior Change Informed by Psychedelics and Psychosis'

Editorial

βBlossom's Take

This theory paper is useful because it gives a more explicit account of why psychedelics and psychosis can look superficially similar but lead to very different outcomes. By separating broadened, hyperassociative processing from self-focus, it offers a testable framing for later work on ego dissolution, hyperreflexivity and behaviour change, without pretending that a conceptual synthesis is itself evidence.

Introduction

Classic psychedelic-assisted therapy has attracted growing attention because trials and population-level analyses suggest these substances can produce enduring psychological and behavioural benefits across diverse conditions, including substance use disorders, depression, end-of-life anxiety, and demoralisation. At a biological level, research indicates classic psychedelics promote neuroplasticity and have anti-inflammatory effects, offering plausible mechanisms for lasting change. Paradoxically, these same compounds have a long history of being described as psychotomimetic; early investigators proposed using psychedelics to model psychosis "from the inside," and subsequent empirical work has noted acute overlaps between psychedelic states and features of early psychosis. Dourron and colleagues set out to resolve this psychotomimetic–psychedelic paradox by proposing self-entropic broadening (SEB) theory. SEB synthesises existing frameworks—notably entropic brain theory (EBT), REBUS, and broaden-and-build theory—by arguing that both classic psychedelics and early psychosis instantiate an entropic processing style (broadened attentional scope, decreased predictability and hyperassociative thinking), but diverge in the degree and direction of self-focus. The review aims to characterise shared cognitive and neural features, specify where and why trajectories differ, and suggest testable predictions and research priorities to explain when entropic states lead to flourishing versus languishing.

Methods

The paper is a theoretical, narrative review and synthesis rather than a primary empirical study. The extracted text does not report a formal systematic search strategy, databases searched, or explicit inclusion/exclusion criteria typical of a systematic review or meta-analysis. Instead, the authors integrate findings from diverse literatures—psychedelic clinical trials and naturalistic studies, psychosis research (especially first-episode psychosis and ultrahigh-risk cohorts), neuroimaging and neurophysiology studies, animal work, and conceptual models such as EBT, REBUS, and broaden-and-build theory. Scope and definitional choices are reported: the review focuses primarily on first-episode psychosis (FEP) and prodromal/ultrahigh-risk (UHR) states to avoid confounding from chronic antipsychotic exposure, and defines "classic psychedelics" as substances whose characteristic subjective and cognitive effects derive largely from serotonin 2A receptor (5-HT2AR) agonism (for example, DMT, psilocybin, LSD, mescaline). The authors draw on experimental pharmacology (including receptor-blocking studies), clinical trial outcomes, qualitative follow-ups, neuroimaging (fMRI, PET) and electrophysiology, and selected animal models to build SEB theory. Analytic approach is conceptual: Dourron and colleagues identify an "entropic processing" construct (reduced filtering, broadened attention, hyperassociative thought, altered salience) and then examine its manifestations across domains (learning/attention, salience attribution, creativity, thalamic connectivity, large-scale networks, and self-experience). Where quantitative findings are available in the extracted text (e.g., select prevalence figures, correlations, and experimental blockade effects), these are cited to support theoretical claims, but no pooled meta-analytic statistics or formal risk-of-bias assessments are reported in the available extraction.

Results

The authors assemble empirical and phenomenological evidence to characterise two core components: entropic processing and differential self-focus. Entropic processing is described as a reduction in schema-driven filtering that broadens attentional scope, increases information richness, and fosters hyperassociative thinking and altered salience. Evidence cited includes acute increases in neural entropy under LSD and psilocybin that predict later increases in openness, language becoming more entropic during LSD, and parallels with early psychosis and creative cognition. Behavioural tasks show shared cognitive signatures: both psychosis and acute psychedelic states demonstrate impaired selective attention and increased attention to irrelevant stimuli (for example, Stroop impairments), and both show altered learning attributable to reduced filtering. Altered salience is reported across both states. In psychosis, aberrant salience is linked empirically to dopaminergic dysregulation and predicts transition in UHR samples; the Aberrant Salience Inventory (ASI) and laboratory tasks capture dimensions such as senses sharpening and impending understanding. Classic psychedelics reliably change the appraisal of ordinary stimuli—sometimes increasing perceived meaning—and recent work has observed increases in aberrant-salience measures during acute LSD; many of these psychedelic effects appear to be mediated via 5-HT2AR signalling and can be attenuated by ketanserin. On creativity, the review notes mixed findings: acute psychedelic administration often impairs formal creativity-task performance (likely due to reduced executive control) while producing subjective feelings of insight; postacute or long-term increases in creative tendencies are plausible but not definitively demonstrated. Neuroimaging data suggest that psychedelic-induced reorganisation of the default mode network (DMN) and increased between-network connectivity may underlie hyperassociative cognition. Thalamic and large-scale network findings are summarised. Classic psychedelics and psychosis both show thalamic–sensorimotor hyperconnectivity in resting-state studies, and under psychedelics this hyperconnectivity correlates with altered perceptual vividness and meaning (one LSD study reported a correlation of about r = 0.58 between thalamic–sensory hyperconnectivity and "changed meaning of percepts"). The DMN is implicated in self-referential processing: acute decreases in DMN integrity are commonly observed with psychedelics and have been linked to ego-dissolution and acute insights, whereas DMN alterations in schizophrenia vary by illness stage (early increases in within-network connectivity versus later decreases). The authors note inconsistent correspondence between imaging modalities (PET, fMRI, MRS), complicating interpretation of prefrontal activity findings. A central empirical contrast concerns self-experience. Psychosis is characterised by a self-disturbance syndrome comprising hyper-reflexivity (exaggerated self-conscious monitoring), diminished self-presence (feelings of unreality or non-mineness), and "disturbed grip" on experience; these features are linked to delusion formation, poor functional outcomes, and suicidality. By contrast, classic psychedelics typically reduce self-focus (hyporeflexivity, ‘‘ego dissolution’’ or "small self" states), while often preserving or even increasing a sense of self-presence; these changes predict enduring therapeutic benefits across clinical indications (for example, correlations between mystical-type or oceanic-boundlessness scores and improvements in depression, anxiety in cancer, and substance use outcomes). The authors cite qualitative interview data and long-term follow-ups where participants report increased appreciation of ordinary life, renewed activity engagement, improved social connectedness, and behaviour change. Neuropharmacological nuances are highlighted. Dopaminergic sensitisation—exemplified by stimulant-induced psychosis and amphetamine challenges—maps well to the self-focused, delusion-prone phenotype. By contrast, classic psychedelic effects hinge on 5-HT2AR agonism, and many subjective and network-level effects (including certain thalamic and DMN alterations) are attenuated by 5-HT2A antagonists like ketanserin. The review also discusses atypical findings: chronic high-frequency LSD exposure in animal models can produce long-lasting changes reminiscent of psychosis, and 5-MeO-DMT (with higher 5-HT1A affinity) shows phenomenological differences and a high rate of brief reactivations in naturalistic use. The review documents prevalence and clinical statistics drawn from the literature: example figures include common delusional themes in FEP (being harmed/attacked/killed 55%, being monitored/followed 48%, being talked/laughed at 30%), high rates of substance-induced psychosis in stimulant users (pooled estimates cited include 42.7% lifetime prevalence of substance-induced psychosis in methamphetamine use disorder and 55.6% for lifetime cocaine-induced psychosis in one meta-analysis), and high rates of self-reported long-term benefit after challenging psychedelic experiences (in one survey 84% reported benefit from their most challenging experience). Finally, the authors identify candidate neural substrates for further work—the claustrum, thalamic subnuclei, and interactions among DMN, frontoparietal control network and salience networks—and review limitations in the existing neuroimaging literature (small samples, limited subnuclear thalamic analyses, and modality discrepancies).

Discussion

Dourron and colleagues interpret the assembled evidence to propose SEB theory: entropic processing (a broadened attentional scope and hyperassociative cognition) is common to both classic psychedelic states and early psychosis, but divergent trajectories arise from differences in self-focus. In this account, psychosis exemplifies entropic processing coupled with increased self-focus (hyper-reflexivity, heightened self-relevance), which fosters maladaptive meaning-making and delusion formation and predicts poorer long-term outcomes. By contrast, classic psychedelics tend to produce entropic processing alongside decreased self-focus (hyporeflexivity, experiences of unity or ‘‘small self’’), which can enable self-distant reflection, psychologically meaningful insights, broadened thought-action repertoires and the building of enduring psychosocial resources, thereby supporting lasting improvements in wellbeing. The authors position SEB relative to prior models: it synthesises and extends entropic brain theory, REBUS, broaden-and-build theory and accounts invoking awe, proposing that decreases in self-focus are the crucial modulator that explains why superficially similar entropic states can lead to flourishing after psychedelic exposure but to illness trajectories in psychosis. They acknowledge neuropharmacological heterogeneity—dopaminergic sensitisation and aberrant dopamine signalling are central in many psychosis presentations and stimulant-induced psychosis, whereas 5-HT2AR agonism is primary for classic psychedelic effects—and argue that multiple ‘‘pharmacological roads’’ can lead to overlapping cognitive phenomenology. Key limitations are acknowledged: SEB is a heuristic model rather than a definitive mechanistic account; the review is not a systematic meta-analysis and the extracted text does not provide a formal search or selection method; entropic processing and reductions in self-focus are not unique to psychedelics and can occur in awe, mindfulness, flow or other states; and extremes in either direction (excessive reduction of self-focus or chronic heavy psychedelic exposure) may have adverse consequences. The authors also emphasise gaps in the evidence base—limited systematic empirical work linking specific acute phenomenology to long-term behaviour change, mixed neuroimaging findings across modalities, sparse studies of thalamic subnuclei and claustrum function, and insufficient qualitative work directly comparing psychosis and psychedelic experiences. From these premises, the review outlines empirical recommendations: use experience-sampling methods to link acute self-focus and entropic indices to real-world outcomes; apply psychosis-derived tasks and measures (e.g., Salience Attribution Test, Aberrant Salience Inventory, Examination of Anomalous Self-Experience) to psychedelic research and vice versa; employ quantitative linguistic markers (entropy in speech, first-person pronoun usage) to index entropic processing and self-focus; test whether adjunctive behavioural interventions delivered in the postacute window amplify enduring gains; and deploy causal neuroimaging tools such as real-time fMRI neurofeedback to probe the DMN and other networks' roles in self-experience. The authors emphasise that confirming SEB's predictions would have implications for optimising therapeutic contexts and for distinguishing risky from reparative entropic experiences.

Conclusion

The authors conclude that SEB theory offers a parsimonious resolution of the psychotomimetic–psychedelic paradox by locating the critical distinction not in entropic processing per se but in how self-focus is altered within entropic states. Classic psychedelics tend to broaden attentional scope while reducing self-focus, fostering self-distant reflection, insights and the building of psychosocial resources; early psychosis combines entropic processing with heightened self-focus, promoting maladaptive meaning-making and worse outcomes. They advocate for rigorous empirical testing of SEB's predictions and for research that bridges psychosis and psychedelic literatures to better understand mechanisms that drive flourishing versus languishing after high-entropy mental states.

References (132)

Papers cited by this study that are also in Blossom

Naturalistic Use of Mescaline Is Associated with Self-Reported Psychiatric Improvements and Enduring Positive Life Changes

Agin-Liebes, G. I., Lancelotta, R., Uthaug, M. V. et al. · ACS Pharmacology and Translational Science (2021)

119 cited
Bridging the Gap? Altered Thalamocortical Connectivity in Psychotic and Psychedelic States

Avram, M., Rogg, H., Korda, A. et al. · Frontiers in Psychiatry (2021)

43 cited
Psychedelic Cognition-The Unreached Frontier of Psychedelic Science

Balaet, M. · Frontiers in Neuroscience (2022)

27 cited
The Challenging Experience Questionnaire: Characterization of challenging experiences with psilocybin mushrooms

Barrett, F. S., Bradstreet, M. P., Leoutsakos, J. M. S. et al. · Journal of Psychopharmacology (2016)

359 cited
Emotions and brain function are altered up to one month after a single high dose of psilocybin

Barrett, F. S., Doss, M. K., Sepeda, N. D. et al. · Scientific Reports (2020)

371 cited
Classic hallucinogens and mystical experiences: phenomenology and neural correlates

Barrett, F. S., Griffiths, R. R. · Current Topics in Behavioral Neurosciences (2017)

265 cited
Validation of the revised Mystical Experience Questionnaire in experimental sessions with psilocybin

Barrett, F. S., Johnson, M. W., Griffiths, R. R. · Journal of Psychopharmacology (2015)

623 cited
Show all 132 references
Intensity of Mystical Experiences Occasioned by 5-MeO-DMT and Comparison With a Prior Psilocybin Study

Barsuglia, J. P., Davis, A. K., Palmer, R. et al. · Frontiers in Psychology (2018)

80 cited
Patient Experiences of Psilocybin-Assisted Psychotherapy: An Interpretative Phenomenological Analysis

Belser, A. B., Agin-Liebes, G. I., Swift, T. C. et al. · Journal of Humanistic Psychology (2017)

300 cited
Self-reported negative outcomes of psilocybin users: A quantitative textual analysis

Bienemann, B., Ruschel, N. S., Campos, M. L. et al. · PLOS ONE (2020)

79 cited
Psilocybin-assisted treatment for alcohol dependence: a proof-of-concept study

Bogenschutz, M. P., Forcehimes, A. A., Pommy, J. A. et al. · Journal of Psychopharmacology (2015)

1150 cited
Classic hallucinogens in the treatment of addictions

Bogenschutz, M. P., Johnson, M. W. · Progress in Neuro-Psychopharmacology and Biological Psychiatry (2016)

225 cited
Pivotal Mental States

Brouwer, A., Carhart-Harris, R. L. · Journal of Psychopharmacology (2020)

145 cited
Effects of N, N-Dimethyltryptamine on Rat Behaviors Relevant to Anxiety and Depression

Cameron, L. P., Benson, C. J., Dunlap, L. E. · ACS Chemical Neuroscience (2018)

167 cited
Survey study of challenging experiences after ingesting psilocybin mushrooms: Acute and enduring positive and negative consequences

Carbonaro, T. M., Bradstreet, M. P., Barrett, F. S. et al. · Journal of Psychopharmacology (2016)

538 cited
Psilocybin for treatment-resistant depression: fMRI-measured brain mechanisms

Carhart-Harris, R. L., Roseman, L., Bolstridge, M. et al. · Scientific Reports (2017)

585 cited
Trial of Psilocybin versus Escitalopram for Depression

Carhart-Harris, R. L., Giribaldi, B., Watts, R. et al. · New England Journal of Medicine (2021)

1334 cited
The entropic brain - revisited

Carhart-Harris, R. L. · Neuropharmacology (2018)

539 cited
Psilocybin with psychological support for treatment-resistant depression: six-month follow-up

Carhart-Harris, R. L., Bolstridge, &. M., Day, C. M. J. et al. · Psychopharmacology (2017)

965 cited
Psychedelics and connectedness

Carhart-Harris, R. L., Erritzoe, D., Haijen, E. C. H. M. et al. · Psychopharmacology (2017)

266 cited
Neural correlates of the psychedelic state as determined by fMRI studies with psilocybin

Carhart-Harris, R. L., Erritzoe, D., Williams, T. et al. · PNAS (2012)

1178 cited
REBUS and the Anarchic Brain: Toward a Unified Model of the Brain Action of Psychedelics

Carhart-Harris, R. L., Friston, K. J. · Pharmacological Reviews (2019)

1128 cited
579 cited
Functional connectivity measures after psilocybin inform a novel hypothesis of early psychosis

Carhart-Harris, R. L., Leech, R., Erritzoe, D. et al. · Schizophrenia Bulletin (2012)

266 cited
The entropic brain: a theory of conscious states informed by neuroimaging research with psychedelic drugs

Carhart-Harris, R. L., Leech, R., Shanahan, M. et al. · Frontiers in Human Neuroscience (2014)

1269 cited
Neural correlates of the LSD experience revealed by multimodal neuroimaging

Carhart-Harris, R. L., Muthukumaraswamy, S., Roseman, L. et al. · PNAS (2016)

875 cited
User perceptions of the benefits and harms of hallucinogenic drug use: A web-based questionnaire study

Carhart-Harris, R. L., Nutt, D. J. · Journal of Substance Use (2010)

107 cited
Psychedelics and the essential importance of context

Carhart-Harris, R. L., Roseman, L., Haijen, E. C. H. M. et al. · Journal of Psychopharmacology (2018)

634 cited
Psilocybin links binocular rivalry switch rate to attention and subjective arousal levels in humans

Carter, O. L., Hasler, F. ;., Pettigrew, J. D. et al. · Psychopharmacology (2007)

149 cited
Development of the Psychological Insight Questionnaire among a sample of people who have consumed psilocybin or LSD

Davis, A. K., Streeter Barrett, F., Griffiths, R. R. et al. · Journal of Psychopharmacology (2021)

165 cited
5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) used in a naturalistic group setting is associated with unintended improvements in depression and anxiety

Davis, A. K., So, S., Lancelotta, R. et al. · The American Journal of Drug and Alcohol Abuse (2019)

139 cited
25 cited
LSD acutely impairs fear recognition and enhances emotional empathy and sociality

Dolder, P. C., Schmid, Y., Müller, F. et al. · Neuropsychopharmacology (2016)

246 cited
Ayahuasca dimethyltryptamine, and psychosis: a systematic review of human studies

Dos Santos, R. G., Hallak, J. E., Bouso, J. C. · Therapeutic Advances in Psychopharmacology (2017)

167 cited
52 cited
Flashback: psychiatric experimentation with LSD in historical perspective

Dyck, E. · Canadian Journal of Psychiatry (2005)

87 cited
A narrative synthesis of research with 5-MeO-DMT

Ermakova, A. O., Dunbar, F., Rucker, J. et al. · Journal of Psychopharmacology (2021)

81 cited
Psychedelics as anti-inflammatory agents

Flanagan, T. W., Nichols, C. D. · International Review of Psychiatry (2018)

256 cited
Enhancement of Creative Expression and Entoptic Phenomena as After-Effects of Repeated Ayahuasca Ceremonies

Frecska, E., Móré, C. E., Vargha, A. et al. · Journal of Psychoactive Drugs (2012)

88 cited
Psychedelics as potential catalysts of scientific creativity and insight

Gandy, S., Bonnelle, V., Jacobs, E. et al. · Drug Science Policy and Law (2022)

24 cited
Persisting Reductions in Cannabis, Opioid, and Stimulant Misuse After Naturalistic Psychedelic Use: An Online Survey

Garcia-Romeu, A., Davis, A. K., Griffiths, R. R. et al. · Frontiers in Psychiatry (2020)

152 cited
Cessation and reduction in alcohol consumption and misuse after psychedelic use

Garcia-Romeu, A., Davis, A. K., Fire Erowid et al. · Journal of Psychopharmacology (2019)

283 cited
Making “bad trips” good: How users of psychedelics narratively transform challenging trips into valuable experiences

Gashi, L., Sandberg, S., Pedersen, W. · International Journal of Drug Policy (2021)

170 cited
Serotonin research: contributions to understanding psychoses

Geyer, M. A., Vollenweider, F. X. · Trends in Pharmacological Sciences (2008)

435 cited
Updating the dynamic framework of thought: Creativity and psychedelics

Girn, M., Mills, C., Roseman, L. et al. · NeuroImage (2020)

139 cited
Psilocybin occasioned mystical-type experiences: immediate and persisting dose-related effects

Griffiths, R. R., Johnson, M. W., Richards, W. A. et al. · Psychopharmacology (2011)

934 cited
Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance

Griffiths, R. R., Richards, W. A., Mccann, U. et al. · Journal of Psychopharmacology (2006)

1671 cited
180 cited
The relationships of classic psychedelic use with criminal behavior in the United States adult population

Hendricks, P. S., Crawford, M. S., Cropsey, K. L. et al. · Journal of Psychopharmacology (2017)

89 cited
Classic psychedelic use is associated with reduced psychological distress and suicidality in the United States adult population

Hendricks, P. S., Thorne, C. B., Clark, B. et al. · Journal of Psychopharmacology (2015)

376 cited
Ketamine-induced modulation of the thalamo-cortical network in healthy volunteers as a model for schizophrenia

Höflich, A., Hahn, A., Küblböck, M. et al. · International Journal of Neuropsychopharmacology (2015)

125 cited
Psychedelics in Psychiatry: Neuroplastic, Immunomodulatory, and Neurotransmitter Mechanisms

Inserra, A., De Gregorio, D., Gobbi, G. · Pharmacological Reviews (2021)

222 cited
Psychedelics not linked to mental health problems or suicidal behavior: A population study.

Johansen, P. Ø., Krebs, T. S. · Journal of Psychopharmacology (2015)

299 cited
Pilot study of the 5-HT2AR agonist psilocybin in the treatment of tobacco addiction

Johnson, M. W., Garcia-Romeu, A., Cosimano, M. P. et al. · Journal of Psychopharmacology (2014)

899 cited
Classic psychedelics: An integrative review of epidemiology, therapeutics, mystical experience, and brain network function

Johnson, M. W., Hendricks, P. S., Barrett, F. S. et al. · Pharmacology and Therapeutics (2019)

518 cited
Human hallucinogen research: guidelines for safety

Johnson, M. W., Richards, W. A., Griffiths, R. R. · Journal of Psychopharmacology (2008)

1173 cited
Does psychedelic therapy have a transdiagnostic action and prophylactic potential?

Kočárová, C., Horacek, J., Carhart-Harris, R. L. · Frontiers in Psychiatry (2021)

94 cited
163 cited
LSD Increases Primary Process Thinking via Serotonin 2A Receptor Activation

Sumiyoshi, T., Kraehenmann, R., Pokorny, D. et al. · Frontiers in Pharmacology (2017)

114 cited
Psychedelics and mental health: a population study

Krebs, T. S., Johansen, P. ˚. Ø. · PLOS ONE (2013)

335 cited
Out of the box: A psychedelic model to study the creative mind

Kuypers, K. P. C. · Medical Hypotheses (2018)

16 cited
Ayahuasca enhances creative divergent thinking while decreasing conventional convergent thinking

Kuypers, K. P. C., Riba, &. J., De La Fuente Revenga, &. M. et al. · Psychopharmacology (2016)

203 cited
Reactions to psilocybin administered in a supportive environment

Leary, T., Litwin, G. H., Metzner, R. · Journal of Nervous and Mental Disease (1977)

244 cited
LSD-induced entropic brain activity predicts subsequent personality change

Lebedev, A. V., Kaelen, M., L€ Ovd En, M. et al. · Human Brain Mapping (2016)

331 cited
Two dose investigation of the 5-HT-agonist psilocybin on relative and global cerebral blood flow

Lewis, C. R., Preller, K. H., Kraehenmann, R. et al. · NeuroImage (2017)

105 cited
Hallucinations Under Psychedelics and in the Schizophrenia Spectrum: An Interdisciplinary and Multiscale Comparison

Leptourgos, P., Fortier-Davy, M., Carhart-Harris, R. L. et al. · Schizophrenia Bulletin (2020)

88 cited
Alterations of consciousness and mystical-type experiences after acute LSD in humans

Liechti, M. E., Dolder, P. C., Schmid, Y. · Psychopharmacology (2016)

202 cited
Hallucinogens and Serotonin 5-HT2A Receptor-Mediated Signaling Pathways

López-Giménez, J. F., González-Maeso, J. · Current Topics in Behavioral Neurosciences (2017)

299 cited
Psychedelics promote structural and functional neural plasticity

Ly, C., Greb, A. C., Cameron, L. P. et al. · Cell Reports (2018)

1134 cited
Mystical experiences occasioned by the hallucinogen psilocybin lead to increases in the personality domain of openness

Maclean, K. A., Johnson, M. W., Griffiths, R. R. · Journal of Psychopharmacology (2011)

904 cited
189 cited
Psychedelic effects of psilocybin correlate with serotonin 2A receptor occupancy and plasma psilocin levels

Madsen, M. K., Fisher, P. M., Burmester, D. et al. · Neuropsychopharmacology (2019)

491 cited
Salvinorin-A induces intense dissociative effects, blocking external sensory perception and modulating interoception and sense of body ownership in humans

Maqueda, A. E., Valle, M., Addy, P. H. et al. · International Journal of Neuropsychopharmacology (2015)

74 cited
Me, myself, bye: regional alterations in glutamate and the experience of ego dissolution with psilocybin

Mason, N. L., Kuypers, K. P. C., Reckweg, J. et al. · Neuropsychopharmacology (2020)

258 cited
Spontaneous and deliberate creative cognition during and after psilocybin exposure

Mason, N. L., Kuypers, K. P. C., Reckweg, J. T. et al. · Translational Psychiatry (2021)

131 cited
Psychedelic Resting-state Neuroimaging: A Review and Perspective on Balancing Replication and Novel Analyses

McCulloch, D. E-W., Knudsen, G. M., Barrett, F. S. et al. · Neuroscience and Biobehavioral Reviews (2022)

114 cited
Psychedelics, meditation, and self-consciousness

Milliere, R., Carhart-Harris, R. L., Roseman, L. et al. · Frontiers in Psychology (2018)

401 cited
Acute effects of lysergic acid diethylamide (LSD) on resting brain function

Felix, M., Stefan, B. · Swiss Medical Weekly (2019)

10 cited
Altered network hub connectivity after acute LSD administration

Müller, F., Dolder, P. C., Schmidt, A. et al. · NeuroImage (2018)

187 cited
Increased thalamic resting state connectivity as a core driver of LSD-induced hallucinations

Lenz, C., Dolder, P. C., Lang, U. E. et al. · Acta Psychiatrica Scandinavica (2017)

147 cited
Psychedelic therapy for smoking cessation: Qualitative analysis of participant accounts

Noorani, T., Garcia-Romeu, A., Swift, T. C. et al. · Journal of Psychopharmacology (2018)

283 cited
Ego-dissolution and psychedelics: validation of the ego-dissolution inventory (EDI)

Nour, M. R., Evans, J., Nutt, D. J. et al. · Frontiers in Human Neuroscience (2016)

475 cited
A review of the clinical effects of psychotomimetic agents

Osmond, H. · Annals of the New York Academy of Sciences (2010)

353 cited
The association of psychedelic use and opioid use disorders among illicit users in the United States

Pisano, V. D., Putnam, N. P., Kramer, H. M. et al. · Journal of Psychopharmacology (2017)

83 cited
A systematic study of microdosing psychedelics

Polito, V., Stevenson, R. J. · PLOS ONE (2019)

235 cited
The fabric of meaning and subjective effects in LSD-induced states depend on serotonin 2A receptor activation

Preller, K. H., Herdener, M., Pokorny, T. et al. · Current Biology (2017)

399 cited
Psilocybin-Induced Deficits in Automatic and Controlled Inhibition are Attenuated by Ketanserin in Healthy Human Volunteers

Quednow, B. B., Kometer, M., Geyer, M. A. et al. · Neuropsychopharmacology (2011)

240 cited
Quality of acute psychedelic experience predicts therapeutic efficacy of psilocybin for treatment-resistant depression

Roseman, L., Nutt, D. J., Carhart-Harris, R. L. · Frontiers in Pharmacology (2018)

805 cited
203 cited
The entropic tongue: Disorganization of natural language under LSD

Sanz, C., Pallavicini, C., Carrillo, F. et al. · Consciousness and Cognition (2021)

34 cited
Acute effects of lysergic acid diethylamide in healthy subjects

Schmid, Y., Enzler, F., Gasser, P. et al. · Biological Psychiatry (2015)

424 cited
117 cited
Associations between lifetime classic psychedelic use and markers of physical health

Simonsson, O., Sexton, J. D., Hendricks, P. S. · Journal of Psychopharmacology (2021)

75 cited
Exploring the therapeutic potential of Ayahuasca: acute intake increases mindfulness-related capacities

Soler, J., Elices, M., Franquesa, A. et al. · Psychopharmacology (2015)

211 cited
Drug models of schizophrenia

Steeds, H., Carhart-Harris, R. L., Stone, J. M. · Therapeutic Advances in Psychopharmacology (2014)

131 cited
Brain serotonin 2A receptor binding predicts subjective temporal and mystical effects of psilocybin in healthy humans

Stenbæk, D. S., Madsen, M. K., Ozenne, B. et al. · Journal of Psychopharmacology (2020)

80 cited
Psychometric evaluation of the altered states of consciousness rating scale (OAV)

Studerus, E., Gamma, A., Vollenweider, F. X. · PLOS ONE (2010)

685 cited
The Associations of Naturalistic Classic Psychedelic Use, Mystical Experience, and Creative Problem Solving

Sweat, N. W., Bates, L. W., Hendricks, P. S. · Journal of Psychoactive Drugs (2016)

48 cited
Cancer at the dinner table: experiences of psilocybin-assisted psychotherapy for the treatment of cancer-related distress

Swift, T. C., Belser, A. B., Agin-Liebes, G. et al. · Journal of Humanistic Psychology (2017)

182 cited
Increased global functional connectivity correlates with LSD-induced ego dissolution

Tagliazucchi, E., Roseman, L., Kaelen, M. et al. · Current Biology (2016)

525 cited
50 cited
Sub-acute and long-term effects of ayahuasca on affect and cognitive thinking style and their association with ego dissolution

Uthaug, M. V., Van Oorsouw, &. K., Kuypers, &. K. P. C. et al. · Psychopharmacology (2018)

213 cited
Shannon entropy of brain functional complex networks under the influence of the psychedelic Ayahuasca

Viol, A., Palhano-Fontes, F., Onias, H. et al. · Scientific Reports (2017)

153 cited
447 cited
Classic Psychedelic Drugs: Update on Biological Mechanisms

Vollenweider, F. X., Smallridge, J. W. · Pharmacopsychiatry (2022)

104 cited
Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action

Vollenweider, F. X., Vollenweider-Scherpenhuyzen, M. F. I., Bäbler, A. et al. · NeuroReport (1998)

1017 cited
Patients’ accounts of increased “Connectedness” and “Acceptance” after psilocybin for treatment-resistant depression

Watts, R., Day, C. M., Krzanowski, J. et al. · Journal of Humanistic Psychology (2017)

568 cited
LSD and creativity: Increased novelty and symbolic thinking, decreased utility and convergent thinking

Wießner, I., Falchi, M., Maia, L. O. et al. · Journal of Psychopharmacology (2022)

41 cited
LSD, madness and healing: Mystical experiences as possible link between psychosis model and therapy model

Wießner, I., Falchi, M., Palhano-Fontes, F. et al. · Psychological Medicine (2021)

52 cited
Prefrontal contributions to the stability and variability of thought and conscious experience

Zamani, A., Carhart-Harris, R. L., Christoff, K. · Neuropsychopharmacology (2021)

50 cited

Cited By (7)

Papers in Blossom that reference this study

The entropic brain today

Carhart-Harris, R. L. · Brain (2026)

Do Psychedelics Mimic Psychosis? Perspectives on Similarities and Differences from Individuals with Lived Experience of Psychosis and Psychedelics

Dourron, H. M., Bradley, M. K., Copes, H. et al. · International Journal of Mental Health and Addiction (2026)

Shame, guilt and psychedelic experience: Results from a prospective, longitudinal survey of real-world psilocybin use

Mathai, D. S., Roberts, D. E., Nayak, S. M. et al. · Journal of Psychedelic Drugs (2025)

9 cited
Reports of self-compassion and affect regulation in psilocybin-assisted therapy for alcohol use disorder: An interpretive phenomenological analysis

Agin-Liebes, G. I., Nielson, E. M., Zingman, M. et al. · Psychology of Addictive Behaviors (2024)

40 cited
5-MeO-DMT: An atypical psychedelic with unique pharmacology, phenomenology & risk?

Dourron, H. M., Nichols, C. D., Simonsson, O. et al. · Psychopharmacology (2023)

23 cited